A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial.
OBJECTIVES: Outer membrane vesicle (OMV) vaccines are used against outbreaks of capsular group B Neisseria meningitidis (MenB) caused by strains expressing particular PorA outer membrane proteins (OMPs). Ferric enterobactin receptor (FetA) is another variable OMP that induces type-specific bactericidal antibodies, and the combination of judiciously chosen PorA and FetA variants in vaccine formulations is a potential approach to broaden protection of such vaccines. METHODS: The OMV vaccine Men...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
(Version of record, pdf, 1.2MB)
- Publisher copy:
- Copyright holder:
- Marsay et al
- Copyright date:
Copyright © 2015 The Authors. Published by Elsevier Ltd on behalf of the The British Infection Association. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record